A press release U.S. Sens. Jeff Merkley and Ron Wyden notes the recently passed Congressional funding package includes $1.142 million to help OHSU and St. Charles Health establish a new psychiatry residency program in Bend, and $2 million for an innovative OHSU demonstration project that aims to improve nurse education and retention.

A press release U.S. Sens. Jeff Merkley and Ron Wyden notes the recently passed Congressional funding package includes $1.142 million to help OHSU and St. Charles Health establish a new psychiatry residency program in Bend, and $2 million for an innovative OHSU demonstration project that aims to improve nurse education and retention.

American Healthcare Leader profiles Mike McCaffrey, who says he brought lessons both from his time as a logistics leader in the Army and a global supply manager at Apple to OHSU, ensuring his colleagues have what they need to serve patients: “We’ve been creating a high level of reliability in what we do so nursing staff and clinical staff can be confident that things will be there for them to do their jobs. If we’re not getting supplies to the right places at the right times, that creates challenges and can even evolve to patient risk. Our vision has always been to have those reliable and efficient services that meet the needs of both staff and patients and fulfill our mission as a service-oriented organization.”

In a HemOnc Today article on the unique circumstances of treating a patient with cancer who is pregnant, Brandon Hayes-Lattin, M.D., says, “There isn’t a giant or robust database on the risks for many chemotherapy drugs in pregnancy, including risk to the fetus. This is difficult when counseling a patient.”

Health Day highlights a survey conducted by Jane Zhu, M.D., and colleagues to assess physicians' views toward private equity ownership.

The Cancer Letter writes a brief on the news that after serving as the OHSU Knight Cancer Institute’s director for more than 17 years, Brian Druker, M.D., will take on a new role as the institute’s chief executive officer and Tom Sellers, Ph.D., will take on the director role.

Central Oregon Daily reports on House Bill 4002 and the state’s aims to boost access to addiction medication and expand treatment options. Todd Korthuis M.D., says, “I think there’s an opportunity for these legislated deflections programs to meaningfully connect people to treatment who are looking for it. And yet I haven’t seen any plans around this, and it matters a lot – how they’re doing it, where they’re doing it and how well funded they are.”

Suzanne Duvall, Ph.D., shares insights on screening for and diagnosing autism. Duvall says, “The most common scenario is that individuals with more nuanced symptoms of autism can be missed in childhood and then go on to receive a diagnosis in adulthood, but in retrospect, the same behavior patterns or social communication [delays] were always present. Autism has a genetic component, thus sometimes, when we provide an ASD diagnosis to a child, the parent notes that they were ‘just like them’ when they were a child and may go on to seek evaluation for an ASD diagnosis themselves.”

Curtis Lachowiez, M.D., moderates a roundtable event on targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.

Nadine Mallak, M.D., discusses the role that theranostic agents play in treating patients with cancer. She says, “The target might be different for different cancers. It could be a ligand, an antigen, or a receptor. It has to be somewhat specific to the given tumor so that the tumor can accept it relative to normal organs.”